Antimicrobial resistance continues to gain momentum with the introduction of the Antibiotic Development to Advance Patient Treatment (ADAPT) Act in the House of Representatives and President Obama’s mention of the issue in his State of the Union Address last month. IDSA continues to advocate for support of the bill on Capitol Hill, to urge lawmakers to consider important additions to the proposed legislation, and to urge President Obama (PDF) to fulfill his State of the Union Address promise. |
As reported in last month’s issue of IDSA News, the ADAPT Act would advance drug development by establishing a new, limited-population antibacterial and antifungal approval pathway for drugs to treat serious or life-threatening infections where there exists an unmet medical need. IDSA first put forward this concept in 2012, and the ADAPT Act is a result of IDSA’s persistent advocacy on this issue.
IDSA worked closely with Reps. Gene Green (D-TX) and Phil Gingrey (R-GA), who is a physician, to develop this legislation, which is an important successor to the GAIN Act, introduced by Reps. Gingrey and Green, supported by IDSA, and signed into law in 2012.
In a joint letter (PDF) to Reps. Gingrey and Green, IDSA, along with several public health and patient organizations, applauded the bill and recommended strengthening a provision in the bill regarding labeling of drugs approved under this pathway. The groups urged lawmakers to require the label to include a prominently placed visual element, such as a logo, to clearly indicate to the healthcare community that these drugs are approved for a limited population and must be used properly.
You can urge Congress to pass ADAPT by visiting IDSA’s Take Action web page, which includes an action alert that makes it easy to email your congressional representatives and urge them to co-sponsor and strengthen the Act.
In addition to efforts on Capitol Hill, the National Institute for Allergy and Infectious Diseases (NIAID) released a new report, NIAID’s Antibacterial Resistance Program: Current Status and Future Directions (PDF), which NIAID regards as an update of its 2008 research agenda published in The Journal of Infectious Diseases. The report includes an update on the Antibacterial Resistance Leadership Group (ARLG), which is co-led by IDSA’s Antimicrobial Resistance Committee chair Henry F. “Chip” Chambers, MD, FIDSA.
< Previous Article | Next Article >